Latest News
PhaseBio initiates second Phase I trial of Vasomera
19 June 2013 - 19 June 2013 - US biopharmaceutical company PhaseBio announced on Tuesday that it has completed a Phase I clinical trial of Vasomera (PB1046) for cardiopulmonary diseases treatment and that it has initiated a second Phase I study.The s...
Gold Standard Diagnostics unveils Lyme disease testing technology
19 June 2013 - 19 June 2013 - US diagnostic solutions company Gold Standard Diagnostics revealed today its new Line Immunoassay technology for Lyme disease testing.Thanks to its latest addition, Gold Standard will provide laboratories with an US FDA-...
BD Biosciences expands research flow cytometers offering
19 June 2013 - 19 June 2013 - BD Biosciences, a unit of Becton, Dickinson and Company (NYSE:BDX), or BD, said today it had introduced its latest research flow cytometer, the BD LSRFortessa X-20 Cell Analyzer.The compact product can be configured with...
Canada's iCo Therapeutics completes enrolment in Phase II trial of antisense inhibitor iCo-007 in DME
19 June 2013 - 19 June 2013 - Canadian biotech group iCo Therapeutics Inc (CVE:ICO) said Tuesday it had finalised the patient enrolment in a Phase II study of its second-generation antisense inhibitor targeting C-raf (ribonucleic acid-mRNA), iCo-007,...
FDA advisory committee to meet over Amarin's Vascepa sNDA in Oct
19 June 2013 - 19 June 2013 - Irish Amarin Corporation plc (NASDAQ:AMRN) said today it had been notified that a US FDA advisory committee will meet on 16 October regarding the supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) cap...